These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18184439)

  • 1. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
    Wu Y; Mohamed H; Chillar R; Ali I; Clayton S; Slamon D; Vadgama JV
    Breast Cancer Res; 2008; 10(1):R3. PubMed ID: 18184439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
    Wu Y; Sarkissyan M; Elshimali Y; Vadgama JV
    PLoS One; 2013; 8(10):e78259. PubMed ID: 24167614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.
    Choi YH; Ahn JH; Kim SB; Jung KH; Gong GY; Kim MJ; Son BH; Ahn SH; Kim WK
    Ann Oncol; 2009 Aug; 20(8):1337-43. PubMed ID: 19221151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
    Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.
    Schmitz KJ; Otterbach F; Callies R; Levkau B; Hölscher M; Hoffmann O; Grabellus F; Kimmig R; Schmid KW; Baba HA
    Mod Pathol; 2004 Jan; 17(1):15-21. PubMed ID: 14631376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
    Tokunaga E; Kimura Y; Oki E; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Ikebe M; Kakeji Y; Baba H; Maehara Y
    Int J Cancer; 2006 Jan; 118(2):284-9. PubMed ID: 16049961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
    Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
    Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERβ and HER-2 expression.
    Wang X; Yi L; Zhu Y; Zou J; Hong Y; Zheng W
    Tumori; 2011; 97(2):185-90. PubMed ID: 21617713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer.
    Wu Y; Khan H; Chillar R; Vadgama JV
    Int J Oncol; 1999 Jun; 14(6):1021-37. PubMed ID: 10339653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of pAKT and CD44v6 overexpression with breast cancer.
    Yu P; Zhou L; Ke W; Li K
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1283-92. PubMed ID: 20157733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
    Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Grell P; Fabian P; Khoylou M; Radova L; Slaby O; Hrstka R; Vyzula R; Hajduch M; Svoboda M
    Int J Oncol; 2012 Oct; 41(4):1204-12. PubMed ID: 22842582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
    Andre F; Nahta R; Conforti R; Boulet T; Aziz M; Yuan LX; Meslin F; Spielmann M; Tomasic G; Pusztai L; Hortobagyi GN; Michiels S; Delaloge S; Esteva FJ
    Ann Oncol; 2008 Feb; 19(2):315-20. PubMed ID: 17804473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
    Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hashizume K; Ono M; Kouno T; Ando M; Tamura K; Katsumata N; Hasegawa T; Kinoshita T; Fujiwara Y
    Med Oncol; 2009; 26(3):344-9. PubMed ID: 19016009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.